+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biosimilars Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 250 Pages
  • January 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5924998
Description Jump to:
The global biosimilars market is on a remarkable growth trajectory during forecast period. It is expected to reach a substantial size of US$ 98 billion by the end of 2031, up from the current industry value of US$ 34 billion.

Market Dynamics

Biosimilars, biologically similar alternatives to existing biologics, are gaining increasing adoption in the healthcare industry. They are used to prevent and treat various chronic diseases, including cancer, diabetes, autoimmune diseases, cardiovascular diseases, and infectious diseases. The rising prevalence of these healthcare issues, coupled with the economic advantages of biosimilars over traditional biologics, is driving market growth.

Revenue Generators

  • Growing Adoption of Biosimilars: Increasing awareness and preference for biosimilars, along with their cost-effectiveness, are major revenue drivers. Biosimilars are particularly vital in addressing chronic diseases, and their adoption is expected to continue rising globally.
  • Increased Organizational Initiatives: Public and private organizations are actively promoting the use of biosimilars over synthetic drug products and conventional biologics, fostering revenue generation opportunities for biosimilar manufacturers. The rapid expansion of the pharmaceutical sector and rising prices of existing biological drugs are further propelling growth.

Challenges Hindering Sales Growth

  • High Manufacturing Costs: The production cost of biosimilars remains relatively high, posing challenges for mass production. Additionally, the complexity of the production process and the rigorous regulatory scrutiny required for biosimilars limit growth opportunities. Ensuring biosimilarity through extensive analytical characterization and regulatory approval procedures can be time-consuming and costly.

Market Trends and Opportunities

  • Discounted Prices: The trend of discounted biosimilar prices, offering substantial benefits to patients, is expected to persist. Manufacturers are increasingly offering price reductions and heavy discounts, driving global biosimilars market growth.
  • Strategic Collaborations: Leading manufacturers are focusing on collaborations and outsourcing production of biosimilar products, which is expected to favor market expansion. Multiple production volumes and production on different scales are being explored for potential profitability.

Regional Analysis

  • Europe and North America: Europe has traditionally been the largest market for biosimilars, followed by North America. However, the biosimilars industry is witnessing significant growth in Asia, particularly in countries like China, India, and Korea. Favorable conditions, including skilled labor, lower manufacturing costs, and simplified regulatory measures, are driving growth in Asian markets.

Key Market Players

Prominent players in the global biosimilars market include Pfizer Inc., Eli Lilly & Company, Sandoz International GMBH, Hospira Inc., Actavis, Inc., Biocon Ltd., Amgen, Inc., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Stada Arzneimittel Ag, Celltrion, Inc., Wockhardt Ltd, and Mylan, Inc.

Biosimilars Industry Research by Category

By Product Type:

  • Recombinant Glycosylated Proteins
  • Recombinant Non-Glycosylated Proteins

By Application:

  • Hematology
  • Growth Hormone Deficiency
  • Oncology
  • Diabetes Autoimmune
  • Disease
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia and Pacific
  • East Asia
  • Middle East and Africa


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Biosimilars Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Production Output and Trade Statistics, 2018 - 2023
3.1. Global Biosimilars Production Output, by Region, Value (US$ Bn) and Volume (Units), 2018 - 2023
3.1.1. North America
3.1.2. Europe
3.1.3. Asia Pacific
3.1.4. Latin America
3.1.5. Middle East and Africa
4. Price Analysis, 2018 - 2023
4.1. Global Average Price Analysis by Product Type, 2018 - 2023
4.2. Prominent Factor Affecting Biosimilars Prices
4.3. Global Average Price Analysis by Region
5. Global Biosimilars Market Outlook, 2018 - 2031
5.1. Global Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Recombinant Glycosylated Proteins
5.1.1.2. Recombinant Non-Glycosylated Proteins
5.2. Global Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Hematology
5.2.1.2. Growth Hormone Deficiency
5.2.1.3. Oncology
5.2.1.4. Diabetes Autoimmune
5.2.1.5. Disease
5.2.1.6. Others
5.3. Global Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Online Pharmacies
5.3.1.3. Retail Pharmacies
5.4. Global Biosimilars Market Outlook, by Region, Value (US$ Bn) and Volume (Units), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. North America
5.4.1.2. Europe
5.4.1.3. Asia Pacific
5.4.1.4. Latin America
5.4.1.5. Middle East & Africa
6. North America Biosimilars Market Outlook, 2018 - 2031
6.1. North America Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Recombinant Glycosylated Proteins
6.1.1.2. Recombinant Non-Glycosylated Proteins
6.2. North America Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Hematology
6.2.1.2. Growth Hormone Deficiency
6.2.1.3. Oncology
6.2.1.4. Diabetes Autoimmune
6.2.1.5. Disease
6.2.1.6. Others
6.3. North America Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Online Pharmacies
6.3.1.3. Retail Pharmacies
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. North America Biosimilars Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. U.S. Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
6.4.1.2. U.S. Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
6.4.1.3. U.S. Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
6.4.1.4. Canada Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
6.4.1.5. Canada Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
6.4.1.6. Canada Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Europe Biosimilars Market Outlook, 2018 - 2031
7.1. Europe Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Recombinant Glycosylated Proteins
7.1.1.2. Recombinant Non-Glycosylated Proteins
7.2. Europe Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Hematology
7.2.1.2. Growth Hormone Deficiency
7.2.1.3. Oncology
7.2.1.4. Diabetes Autoimmune
7.2.1.5. Disease
7.2.1.6. Others
7.3. Europe Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Online Pharmacies
7.3.1.3. Retail Pharmacies
7.3.2. Attractiveness Analysis
7.4. Europe Biosimilars Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Germany Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.2. Germany Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.3. Germany Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.4. U.K. Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.5. U.K. Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.6. U.K. Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.7. France Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.8. France Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.9. France Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.10. Italy Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.11. Italy Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.12. Italy Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.13. Turkey Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.14. Turkey Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.15. Turkey Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.16. Russia Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.17. Russia Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.18. Russia Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.19. Rest of Europe Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.20. Rest of Europe Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.1.21. Rest of Europe Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Asia Pacific Biosimilars Market Outlook, 2018 - 2031
8.1. Asia Pacific Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Recombinant Glycosylated Proteins
8.1.1.2. Recombinant Non-Glycosylated Proteins
8.2. Asia Pacific Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Hematology
8.2.1.2. Growth Hormone Deficiency
8.2.1.3. Oncology
8.2.1.4. Diabetes Autoimmune
8.2.1.5. Disease
8.2.1.6. Others
8.3. Asia Pacific Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Online Pharmacies
8.3.1.3. Retail Pharmacies
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Asia Pacific Biosimilars Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. China Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.2. China Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.3. China Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.4. Japan Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.5. Japan Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.6. Japan Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.7. South Korea Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.8. South Korea Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.9. South Korea Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.10. India Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.11. India Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.12. India Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.13. Southeast Asia Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.14. Southeast Asia Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.15. Southeast Asia Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.16. Rest of Asia Pacific Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.17. Rest of Asia Pacific Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.1.18. Rest of Asia Pacific Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Latin America Biosimilars Market Outlook, 2018 - 2031
9.1. Latin America Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.1.1. Key Highlights
9.1.1.1. Recombinant Glycosylated Proteins
9.1.1.2. Recombinant Non-Glycosylated Proteins
9.2. Latin America Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.2.1. Key Highlights
9.2.1.1. Hematology
9.2.1.2. Growth Hormone Deficiency
9.2.1.3. Oncology
9.2.1.4. Diabetes Autoimmune
9.2.1.5. Disease
9.2.1.6. Others
9.3. Latin America Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.3.1. Key Highlights
9.3.1.1. Hospital Pharmacies
9.3.1.2. Online Pharmacies
9.3.1.3. Retail Pharmacies
9.3.2. BPS Analysis/Market Attractiveness Analysis
9.4. Latin America Biosimilars Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1. Key Highlights
9.4.1.1. Brazil Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1.2. Brazil Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1.3. Brazil Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1.4. Mexico Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1.5. Mexico Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1.6. Mexico Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1.7. Argentina Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1.8. Argentina Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1.9. Argentina Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1.10. Rest of Latin America Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1.11. Rest of Latin America Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.1.12. Rest of Latin America Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
9.4.2. BPS Analysis/Market Attractiveness Analysis
10. Middle East & Africa Biosimilars Market Outlook, 2018 - 2031
10.1. Middle East & Africa Biosimilars Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.1.1. Key Highlights
10.1.1.1. Recombinant Glycosylated Proteins
10.1.1.2. Recombinant Non-Glycosylated Proteins
10.2. Middle East & Africa Biosimilars Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.2.1. Key Highlights
10.2.1.1. Hematology
10.2.1.2. Growth Hormone Deficiency
10.2.1.3. Oncology
10.2.1.4. Diabetes Autoimmune
10.2.1.5. Disease
10.2.1.6. Others
10.3. Middle East & Africa Biosimilars Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.3.1. Key Highlights
10.3.1.1. Hospital Pharmacies
10.3.1.2. Online Pharmacies
10.3.1.3. Retail Pharmacies
10.3.2. BPS Analysis/Market Attractiveness Analysis
10.4. Middle East & Africa Biosimilars Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1. Key Highlights
10.4.1.1. GCC Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.2. GCC Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.3. GCC Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.4. South Africa Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.5. South Africa Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.6. South Africa Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.7. Egypt Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.8. Egypt Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.9. Egypt Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.10. Nigeria Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.11. Nigeria Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.12. Nigeria Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.13. Rest of Middle East & Africa Biosimilars Market by Product Type, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.14. Rest of Middle East & Africa Biosimilars Market by Application, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.1.15. Rest of Middle East & Africa Biosimilars Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2018 - 2031
10.4.2. BPS Analysis/Market Attractiveness Analysis
11. Competitive Landscape
11.1. By End User vs by Application Heatmap
11.2. Company Market Share Analysis, 2023
11.3. Competitive Dashboard
11.4. Company Profiles
11.4.1. Pfizer Inc.
11.4.1.1. Company Overview
11.4.1.2. Product Portfolio
11.4.1.3. Financial Overview
11.4.1.4. Business Strategies and Development
11.4.2. Sandoz International GMBH
11.4.2.1. Company Overview
11.4.2.2. Product Portfolio
11.4.2.3. Financial Overview
11.4.2.4. Business Strategies and Development
11.4.3. Eli Lily & Company
11.4.3.1. Company Overview
11.4.3.2. Product Portfolio
11.4.3.3. Financial Overview
11.4.3.4. Business Strategies and Development
11.4.4. Hospira Inc.
11.4.4.1. Company Overview
11.4.4.2. Product Portfolio
11.4.4.3. Financial Overview
11.4.4.4. Business Strategies and Development
11.4.5. Biocon Ltd.
11.4.5.1. Company Overview
11.4.5.2. Product Portfolio
11.4.5.3. Financial Overview
11.4.5.4. Business Strategies and Development
11.4.6. Actavis, Inc.
11.4.6.1. Company Overview
11.4.6.2. Product Portfolio
11.4.6.3. Financial Overview
11.4.6.4. Business Strategies and Development
11.4.7. Cipla Ltd
11.4.7.1. Company Overview
11.4.7.2. Product Portfolio
11.4.7.3. Financial Overview
11.4.7.4. Business Strategies and Development
11.4.8. Teva Pharmaceutical Industries, Ltd.
11.4.8.1. Company Overview
11.4.8.2. Product Portfolio
11.4.8.3. Financial Overview
11.4.8.4. Business Strategies and Development
11.4.9. Dr. Reddy’s Laboratories Ltd
11.4.9.1. Company Overview
11.4.9.2. Product Portfolio
11.4.9.3. Financial Overview
11.4.9.4. Business Strategies and Development
11.4.10. Celltrion, Inc.
11.4.10.1. Company Overview
11.4.10.2. Product Portfolio
11.4.10.3. Financial Overview
11.4.10.4. Business Strategies and Development
11.4.11. Stada Arzeimittel Ag
11.4.11.1. Company Overview
11.4.11.2. Product Portfolio
11.4.11.3. Financial Overview
11.4.11.4. Business Strategies and Development
11.4.12. Mylan, Inc.
11.4.12.1. Company Overview
11.4.12.2. Product Portfolio
11.4.12.3. Financial Overview
11.4.12.4. Business Strategies and Development
11.4.13. Wockhardt Ltd.
11.4.13.1. Company Overview
11.4.13.2. Product Portfolio
11.4.13.3. Financial Overview
11.4.13.4. Business Strategies and Development
12. Appendix
12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms and Abbreviations

Companies Mentioned

  • Pfizer Inc.
  • Sandoz International GMBH
  • Eli Lily & Company
  • Hospira Inc.
  • Amgen, Inc.
  • Biocon Ltd.
  • Actavis, Inc.
  • Cipla Ltd.
  • Teva Pharmaceutical Industries, Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Celltrion, Inc.
  • Stada Arzeimittel Ag
  • Mylan, Inc.
  • Wockhardt Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biosimilar Insulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Biosimilar Insulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 250 Pages
  • Global
Biosimilar Contract Manufacturing Market Analysis & Forecast to 2024-2034 - Product Image

Biosimilar Contract Manufacturing Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Insulin Biosimilar Market by Type of Insulin, by Mode of Administration, by Therapeutic Application, by Distribution Channel, and by Region - Product Image

Insulin Biosimilar Market by Type of Insulin, by Mode of Administration, by Therapeutic Application, by Distribution Channel, and by Region

  • Report
  • 200 Pages
  • Global
From
Oncology Biosimilars Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Cancer Type, and Distribution Channel - Product Image

Oncology Biosimilars Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Cancer Type, and Distribution Channel

  • Report
  • 150 Pages
  • Global
From
Insulin biosimilars Global Market Report 2024 - Product Image

Insulin biosimilars Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.